NeuroSearch Fires Workers to Cut Costs, Advance Drug
This article is for subscribers only.
NeuroSearch A/S, the maker of an experimental Huntington’s disease treatment, said it will fire about 20 percent of its employees and take other measures to cut annual costs by about 100 million kroner ($17 million) by 2012.
The company is making several changes to executive management, including a new chief financial officer, and will establish a new drug discovery unit this month, Patrik Dahlen, who became chief executive officer in August, also said in a statement today.